Jonathan Davis, MD, MPHS's Avatar

Jonathan Davis, MD, MPHS

@jonathandavishf.bsky.social

Director @sfhealthnetwork HF Program Zuckerberg SF General Hospital @zsfgcare @ucsfcardiology. New Dad x2! Alum @WUSTLmed⬅️ @UCSFmedicine⬅️ @cornell he/his/him

123 Followers  |  68 Following  |  15 Posts  |  Joined: 14.11.2024  |  1.694

Latest posts by jonathandavishf.bsky.social on Bluesky

9/29 I start at Mercy in St. Louis!
After reflection & emotional debate, we’ve moved to STL. Working at ZSFG/UCSF has been a profound privilege. The community, patients, & colleagues gave me more than I can ever express. Please know how grateful I am to have been part of this extraordinary team.

29.09.2025 03:19 — 👍 0    🔁 0    💬 0    📌 0

Thank you! Very honored!!

18.09.2025 14:51 — 👍 1    🔁 0    💬 0    📌 0
Post image Post image

Honored beyond words to receive the 2025 @ucsfmedicine.bsky.social at @zsfgcare.bsky.social Exceptional Physician Award. It is an incredible privilege to work alongside everyone across the SFHN. Thank you!

09.06.2025 01:56 — 👍 2    🔁 0    💬 1    📌 0
Preview
The Short and Sweet on Sodium–Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure Heart failure (HF) affects 6 million people in the US, and type 2 diabetes (T2D) is a significant risk factor for HF. Since 2008, regulatory agencies have required cardiovascular safety trials

Short & sweet! Check out our review of #SGLT2i & #GLP1RA in #HeartFailure! Great work Jose Lopez & team! @ucsfcardiology.bsky.social @amitgoyalmd.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jimjanuzzi.bsky.social @sjgreene-md.bsky.social

www.uscjournal.com/articles/sho...

13.05.2025 23:14 — 👍 5    🔁 2    💬 1    📌 0

NEW! Patients versions of the #Hypertension guidelines

Need clear, reliable guidance for your patients with hypertension? The ESC has just released the patient-friendly version of its 2024 ESC Guidelines on management of elevated blood pressure and hypertension.

18.04.2025 12:42 — 👍 4    🔁 4    💬 2    📌 0
Preview
GLP-1RAs and SGLT2is for Type 2 Diabetes and Alzheimer Disease This population-based cohort study examines the association of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors with the risk of Alzheimer disease and related de...

#SGLT2i & #GLP1RA; not just for the heart... or kidneys... or diabetes! In ppl w DM2, GLP-1RAs & SGLT2is were associated w ⬇️ risk of Alzheimer disease & related dementias vs other glucose-lowering drugs. @robmentz.bsky.social @jama.com @noshreza.bsky.social @jimjanuzzi.bsky.social
ja.ma/3E3vWRn

16.04.2025 21:29 — 👍 3    🔁 0    💬 0    📌 0
Preview
She was homeless in S.F., hooked on cocaine and her body was failing. Then she got a heart transplant She was homeless in S.F., hooked on cocaine and her body was failing. Then she got a heart transplant.

Thank you @sfchronicle.com for sharing Pamela's incredible journey from homelessness/addiction to ultimately 💓 transplant! Hopefully her story is can inspire pts & providers alike. @zsfgcare.bsky.social @ucsfhealth.bsky.social
www.sfchronicle.com/sf/article/h...

23.01.2025 23:51 — 👍 3    🔁 2    💬 0    📌 0
Preview
New and future heart failure drugs - Nature Cardiovascular Research Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...

Check out this great review of new & emerging treatments for #HeartFailure from #UCSFCardiology Leila Haghighat, Colette DeJong & John Teerlink.
@natrevcardiol.bsky.social @ucsfhealth.bsky.social @robmentz.bsky.social @dranulala.bsky.social @sjgreene-md.bsky.social
nature.com/articles/s44...

19.12.2024 00:00 — 👍 2    🔁 2    💬 0    📌 0
Post image

Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social
www.jointcommission.org/resources/aw...

19.12.2024 21:48 — 👍 1    🔁 1    💬 0    📌 0
Post image

Incredible honor for #ZSFG to be awarded the 2024 Bernard J. Tyson National Award for Excellence in Pursuit of Healthcare Equity from The Joint Commission & Kaiser Permanente! #LucasZierMD @ucsfhealth.bsky.social
www.jointcommission.org/resources/aw...

19.12.2024 21:48 — 👍 1    🔁 1    💬 0    📌 0
Preview
New and future heart failure drugs - Nature Cardiovascular Research Haghighat et al. provide an overview of the newest advances in heart failure drugs, describing their mechanisms of action and performance in recent clinical trials, and discuss the most promising futu...

Check out this great review of new & emerging treatments for #HeartFailure from #UCSFCardiology Leila Haghighat, Colette DeJong & John Teerlink.
@natrevcardiol.bsky.social @ucsfhealth.bsky.social @robmentz.bsky.social @dranulala.bsky.social @sjgreene-md.bsky.social
nature.com/articles/s44...

19.12.2024 00:00 — 👍 2    🔁 2    💬 0    📌 0
Preview
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…

Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation.
@jaccjournals.bsky.social
www.sciencedirect.com/science/arti...

06.12.2024 05:32 — 👍 7    🔁 6    💬 0    📌 0
Post image

Management of Iron Deficiency in Heart Failure: Practical Considerations & Implementation of Evidence-Based Iron Supplementation

#CardioSky #JACCHF
@jaccjournals.bsky.social @robmentz.bsky.social @dranulala.bsky.social @hfsa.bsky.social @accintouch.bsky.social
www.jacc.org/doi/10.1016/...

09.12.2024 20:58 — 👍 10    🔁 6    💬 1    📌 0

Here’s the 3 min video our team at ZSFG made to highlight our work. Check it out! We want to partner w other safety net systems to improve care delivery! #LucasZierMD
#UCSFCardiology #UCSFIMChiefs @sfhealthplan.bsky.social @hfsa.bsky.social @accintouch.bsky.social

vimeo.com/1032042870/2...

06.12.2024 16:41 — 👍 2    🔁 1    💬 0    📌 0

Here’s the 3 min video our team at ZSFG made to highlight our work. Check it out! We want to partner w other safety net systems to improve care delivery! #LucasZierMD
#UCSFCardiology #UCSFIMChiefs @sfhealthplan.bsky.social @hfsa.bsky.social @accintouch.bsky.social

vimeo.com/1032042870/2...

06.12.2024 16:41 — 👍 2    🔁 1    💬 0    📌 0
Preview
Revisiting ICD Therapy for Primary Prevention in Patients With Heart Failure and Reduced Ejection Fraction Implantable cardioverter-defibrillators (ICDs) are recommended to reduce the risk of sudden cardiac death (SCD) in patients with heart failure with re…

Check out our extensive review on contemporary role for ICD in era of improved GDMT led by Amin Yehya, MD. We also propose pragmatic guidance for shared decision-making discussions for primary ICD implantation.
@jaccjournals.bsky.social
www.sciencedirect.com/science/arti...

06.12.2024 05:32 — 👍 7    🔁 6    💬 0    📌 0
Post image Post image

We are thrilled to be honored with the 2024 California Assoc of Public Hospitals (CAPH)/Safety-net Institute (SNI) Quality Leaders Award for Equity for our work leveraging #AI & machine learning in our #EMR to better identify & care for high risk ppl w #HeartFailure

06.12.2024 00:09 — 👍 1    🔁 0    💬 0    📌 1
Preview
41st Annual Advances in Heart Disease

No plans this weekend? Not too late to sign up for the 41st Annual #UCSF #ZSFG Advances in Heart Disease CME! We have a fantastic lineup ready to go!
@accintouch.bsky.social @ahascience.bsky.social @hfsa.bsky.social @aspcardio.bsky.social

virtualce.ucsf.edu/advances-in-...

04.12.2024 16:47 — 👍 1    🔁 2    💬 0    📌 0
Post image Post image

Novel ExCiTe approach aimed at improving trainee recruitment into AHFTC. Great work Edan Zitelny, Rachna Kataria & team @noshreza.bsky.social
@cardionerds.bsky.social @robmentz.bsky.social @dranulala.bsky.social @jcardfail.bsky.social @shelleyzieroth.bsky.social
onlinejcf.com/article/S107...

23.11.2024 04:51 — 👍 15    🔁 7    💬 0    📌 1
Preview
Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY (UPDATED) Part 2 of this 7,000-patient trial suffered from discontinuations and low event rates: still, early MRAs did not impact CV events.

#Spironolactone given to patients who have undergone PCI following an #AMI has no impact on ☠️ from CV causes, or on a range of CV events including new or worsening HF ( #CLEAR SYNERGY )

www.tctmd.com/news/spirono...
@shelleywood.bsky.social @shelleyzieroth.bsky.social @drrajivsankar.bsky.social

17.11.2024 17:11 — 👍 2    🔁 2    💬 0    📌 1

#AHA24 #CardioSky

17.11.2024 00:13 — 👍 6    🔁 1    💬 0    📌 0

@accintouch.bsky.social

16.11.2024 19:01 — 👍 2    🔁 0    💬 0    📌 0
Post image Post image Post image Post image

#LBCT #SUMMIT trial #AHA24
💥 Treatment with tirzepatide led to ⤵️risk of a composite of death from cardiovascular 🫀 causes or worsening heart failure 🆚 placebo and improved health status in patients with HFpEF+obesity
📎 @NEJM www.nejm.org/doi/full/10....

16.11.2024 15:16 — 👍 38    🔁 22    💬 2    📌 1
Video thumbnail

BPROAD presented at #AHA24 showed in those w/ type 2 diabetes & elevated systolic blood pressure (SBP), intensive SBP lowering (<120 mmHg) reduced major adverse CV events (MACE) by 21% compared to standard treatment (<140 mmHg).

Watch this for one attendee’s take on the data.

16.11.2024 18:04 — 👍 9    🔁 9    💬 0    📌 0

1st post!

The 3 rules of #GDMTWorks for #HFrEF:
1. Start more
2.⬆️doses
3. Keep them going
#QuadTherapy: BB + ARNI + MRA + SGLT2-I. 75% RR reduction w NNT of <4!! #cardiology #cardiosky @ahascience.bsky.social @robmentz.bsky.social @drmarthagulati.bsky.social

16.11.2024 18:31 — 👍 11    🔁 4    💬 1    📌 1

@jonathandavishf is following 20 prominent accounts